BioPharmSignal logoBioPharmSignal

Biotech News

Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue

Xeris Pharmaceuticals (XERS)Xeris PharmaceuticalsEarnings

Anticipates full year 2025 total revenue of $292 million , exceeding the guidance range of $285-$290 million and reflecting growth of 44% compared to the prior year Expects fourth quarter and full year 2025 Recorlev ® net revenue of $45 million and $139 million , respectively Full-year 2025

Related news

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

HRMYHarmony Biosciences2026-07-16 12:30 EST

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

CLNNClene Inc.2026-08-14 12:30 EST

Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights

AXSMAxsome2026-08-10 11:00 EST

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

ANVSAnnovis Bio2026-08-14 12:00 EST

Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results

TNXPTonix Pharmaceuticals2026-08-10 11:00 EST

Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights

NBIXNeurocrine Biosciences2026-07-30 20:01 EST

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

ECORelectroCore2026-08-06 20:05 EST

electroCore Announces Second Quarter 2026 Financial Results

View all latest news

Xeris Pharmaceuticals

Specialty Biopharmaceutical Portfolio Xeris Biopharma develops and commercializes products across endocrinology and neurology, using formulation technologies to improve administration and treatment reliability. Endocrine Products Recorlev is an oral cortisol-synthesis inhibitor for endogenous hypercortisolemia in Cushing's syndrome....

Recent company news

XERSXeris Pharmaceuticals2026-08-06 11:00 EST

Xeris Biopharma Reports Second Quarter 2026 Financial Results

XERSXeris Pharmaceuticals2026-07-23 11:30 EST

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

XERSXeris Pharmaceuticals2026-07-02 20:05 EST

CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

XERSXeris Pharmaceuticals2026-06-30 11:00 EST

Xeris Announces Updates to Its Board of Directors

Stock data

Close
8.70 USD
Market cap
1.04B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States